Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22792833 | 0.87 | STS (0.35) | STSCYP2B6CYP1A2 | |
| SCHEMBL22915707 | 0.77 | STS (0.44) | STSCYP2B6CA1CA9CYP1A2 | |
| SCHEMBL21142420 | 0.74 | STS (0.45) | STSCYP2B6CYP1A2 | |
| SCHEMBL13392165 | 0.74 | CYP2B6 (0.40) | STSCYP2B6CYP1A2 | |
| SCHEMBL8404584 | 0.74 | STS (0.40) | STSCYP2B6CA1CA9CYP1A2 | |
| SCHEMBL2087404 | 0.69 | STS (0.40) | STSCYP2B6CA1CA9 | |
| SCHEMBL32689451 | 0.69 | STS (0.44) | STSCYP2B6CA1CA9CYP1A1 | |
| SCHEMBL17186171 | 0.69 | STS (0.41) | STSCYP2B6CA1CA9 | |
| SCHEMBL22792432 | 0.69 | STS (0.37) | STSCYP2B6CA1CA9CYP1A1 | |
| SCHEMBL12316628 | 0.68 | KDM4E (0.36) | STSCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166170-A1 | SYNTHESIS OF AVRAINVILLAMIDE, STEPHACIDIN B, AND ANALOGUES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-07-07 | — | — | US | disclosed |
| US-7902196-B2 | Synthesis of avrainvillamide, strephacidin B, and analogues thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-03-08 | — | — | US | disclosed |
| US-20090143581-A1 | SYNTHESIS OF AVRAINVILLAMIDE, STREPHACIDIN B, AND ANALOGUES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166170-A1 | SYNTHESIS OF AVRAINVILLAMIDE, STEPHACIDIN B, AND ANALOGUES THEREOF | MDN1, VASP, ATRIP | STS 3933/4885CYP2B6 4114/4885CA1 900/4885 |
| US-20090143581-A1 | SYNTHESIS OF AVRAINVILLAMIDE, STREPHACIDIN B, AND ANALOGUES THEREOF | MDN1, BIRC3, STAMBP | STS 2264/4885CYP2B6 4427/4885CA1 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.